Member Info for BuenaVista

@ Wast3d, re "This, and the other board I also posted on are the two clean energy firms I handpicked to research, off the back of checking out some clean energy ETFs but deciding that as I liked the sound of this and the other (AFC), I'd rather hold stakes of my own and not via an ETF."

This is the AFC board. Take your time. Don't let confusion clpoud your judgement.

And re " Frankly, if you think posts on this site can influence heavily, that's just naive." Try telling that to our resident bashers, particularly the odiously prolific Ade, Daz, Garonne, Gitfinger and DW, sad twats who seem to have no life except for spitting bile on here.

We'll know when they light the 'W' sign up in the sky.

I agree RD but it is important to define AVA6000's parameters first, not just for AVA6000 itself but for the pre|CISION platform as a whole. Although, as AVA3996 has a different leaving group, so the 5140 work can't transfer across, there will be a lot of work need doing on that drug's pro-drug capability (as well as the 'new' bortezomib analogue efficacy.

It is worth bearing in mind that no appreciable work has been reported on any follow-on pipeline pre|CISION drugs. Work on AVA6000 and AVA3996 started way back with Professor William Bachovchin at Tufts University Medical School. I have never seen any others exemplified, which is a good thing (if they really haven't been exemplified), as once exemplified the patent life, if patentable because non-obvious, starts running down.

Also agree about Affimers, although novel Affimers can be patented at any time whilst the basic tech has patent protection if they are shown to have commercial possibilities. But yeah, lots of academic papers, very little in the way of commercial partnerships.

As regards the 'university research approach' I thought Science Day was a real missed opportunity. What a hotchpotch of practical information about pre|CISION and deep, detailed lectures about complex topics with nothing tying the whole lot together. Could have had an overview of cancer treatments (showing where AVA6000 fitted in) and another on the causes and severity of chemo side-effects (and how AVA6000 seems to obviate most of them). Keep it relevant to the matter in hand! It wasn't a medical school module.

Meeja is a trader but not, in my current opinion, a basher. I have nothing against traders, per se. It's when they try to adversely affect investors' personal wealth with their lies and scummy behaviour that I lose all respect for them.

Add MelvinAFC

SP went from 11/12 to 16 and is now at 14.5. If you bought at 12 as you said you were planning to you should have sold at 16 and made your little profit.

Not before the SDMC recommended the new dosage. That needed to be announced asap and was on 21 June, so no, to all intents and purposes C6 will not have started BEFORE 21 June.

It's you. What drop are you talking about? What "huge spike"?

If we're now thinking that AFC's old L Series was rather bulky to be being shipped around the world with Extreme E, take a look at the monster Energys has produced for ENOWA to use in Season 3!

https://www.extreme-e.com/en/news/815_Extreme-E-delivers-successful-showcase-of-Hydrogen-Fuel-Cell-system-provided-by-ENOWA

"Portable energy source" is doing a lot of heavy lifting here.

https://energys.com.au/green-hydrogen-news/megawatt-fuel-cell-powers-electic-race-cars-at-extreme-e-saudi-arabia

https://energys.com.au/hydrogen-power

Thank you MCB55. I thought something was said about it at the AGM but was hoping for chapter and verse - who said it and at what time point in the webcast!

For standard doxorubicin it is a simple matter of all the dose administered being counted in the MLCD as it is all systemically available in the circulatory system to attack heart tissue. For AVA6000 it is more complicated to account for all the systemic doxorubicin as it first has to be released by cleavage of AVA6000 by FAP. PK calculations of concentration over time (area under the curve) are needed to be able to do this.

However it must be obvious from what has appeared in RNSes - multiples of the standard doxorubicin dose, patients continuing on it, and hope to treat patients at higher effective doses of doxorubicin and for longer - that the MLCD is calculated on systemic doxorubicin. However, the market has not been officially told this. It came out explicitly at the AGM as part of the 'no new material information'. I'd say it was pretty damned material for the many (potential) investors who couldn't and didn't put 2 and 2 together.

Coming back to the systemic doxorubicin from AVA6000, I should think this might well vary from cancer type to cancer type, from patient to patient and (for each patient) from time to time, so some sort of monitoring of systemic free doxorubicin would be needed, assessments of heart function and/or a very wide margin of safety allowed. No doubt/hopefully they are collecting this sort of data during the trial. There was mention of using FAP PET/CT imaging last year. I took that to mean they would be assessing the amount of FAP in the body and where it was and using that as a surrogate for release of free doxorubicin. I'll be interested to see how they tackle and resolve this issue.

Donkeyeeyore, MLCD is the abbreviation I used for 'maximum lifetime cumulative dose' in my earlier post. Variations MCLD, MCD or MLD can also be used.

MTD is akin to how many glasses of wine can you drink of an evening before you get a serious health reaction.

MLCD is akin to how many glasses of wine can you drink over your lifetime before serious health problems start to appear.

Here is the MLCD information specifically for doxorubicin (original brand name Adriamycin): https://www.drugs.com/medical-answers/lifetime-cumulative-dose-adriamycin-3537856/

Flagged as bollucks yesterday.

Yes Donkeyeeyore, there is a difference. Google the terms.

I don't believe Avacta has officially said how the maximum lifetime cumulative dose is defined for AVA6000 or whether they have been given permission to exceed the 450-550mg/m² doxorubicin (equivalent) MLCD.

What data do you think might come out soon?

MM is now a private small cap investor and trader. He has a trading pot. When he tweets positive stuff when the SP is depressed, the SP usually goes up. And usually comes back down again unless there is positive news from the company. Are you saying you know that he doesn't trade these spikes?

Or maybe just Twitter chatter (MM buying more today) is getting people excited.

https://twitter.com/MylesMcNulty/status/1686684611152101376

Not inconceivable that this just turns out to be what is in effect a pump and dump by MM. I hope so as I missed the trigger. Will wait to see whether it comes back down. If it doesn't, then I'll be less under water than I was yesterday...

Interesting that they are administering a small peptide orally...

AOH1996: https://en.wikipedia.org/wiki/AOH1996

Trial details: https://classic.clinicaltrials.gov/ct2/show/NCT05227326?term=AOH1996&draw=2&rank=1

From the Sky News item: "The new drug has been in development for 20 years, and is now undergoing pre-clinical research in the US." Sky News probably not the most respected peer-review news service.

.

If you want to check for yourself whether a poster adds value to the BB (which does include critically questioning the company's activities), then check out the posting history. If you find it is just a stream of negativity (with maybe spasms of positivity when they are temporarily invested), then you can decide whether to take notice of that account's posts, ignore them or filter the account.